1. Home
  2. BKE vs TNGX Comparison

BKE vs TNGX Comparison

Compare BKE & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Buckle Inc. (The)

BKE

Buckle Inc. (The)

HOLD

Current Price

$44.41

Market Cap

2.7B

ML Signal

HOLD

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

HOLD

Current Price

$20.23

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKE
TNGX
Founded
1948
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.9B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
BKE
TNGX
Price
$44.41
$20.23
Analyst Decision
Hold
Strong Buy
Analyst Count
1
10
Target Price
$53.00
$21.78
AVG Volume (30 Days)
437.2K
2.5M
Earning Date
05-22-2026
05-08-2026
Dividend Yield
7.96%
N/A
EPS Growth
6.43
26.89
EPS
4.14
N/A
Revenue
$1,297,835,000.00
$62,384,000.00
Revenue This Year
$5.10
N/A
Revenue Next Year
$4.99
N/A
P/E Ratio
$10.52
N/A
Revenue Growth
6.58
48.29
52 Week Low
$42.39
$3.77
52 Week High
$61.69
$28.41

Technical Indicators

Market Signals
Indicator
BKE
TNGX
Relative Strength Index (RSI) 32.56 42.30
Support Level N/A $6.77
Resistance Level $56.45 $22.01
Average True Range (ATR) 1.79 1.47
MACD -0.44 -0.06
Stochastic Oscillator 19.26 6.95

Price Performance

Historical Comparison
BKE
TNGX

About BKE Buckle Inc. (The)

Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Share on Social Networks: